These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15006725)

  • 1. Protein crystals for the delivery of biopharmaceuticals.
    Basu SK; Govardhan CP; Jung CW; Margolin AL
    Expert Opin Biol Ther; 2004 Mar; 4(3):301-17. PubMed ID: 15006725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of large biopharmaceuticals from cardiovascular stents: a review.
    Takahashi H; Letourneur D; Grainger DW
    Biomacromolecules; 2007 Nov; 8(11):3281-93. PubMed ID: 17929968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicines for delivery of therapeutic proteins and biopharmaceuticals.
    Sarmento B
    Ther Deliv; 2010 Aug; 1(2):231-5. PubMed ID: 22816130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid nanoparticles for the delivery of biopharmaceuticals.
    Silva AC; Amaral MH; Lobo JM; Lopes CM
    Curr Pharm Biotechnol; 2015; 16(4):291-302. PubMed ID: 25601601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel delivery technologies for protein and peptide therapeutics.
    Kumar TR; Soppimath K; Nachaegari SK
    Curr Pharm Biotechnol; 2006 Aug; 7(4):261-76. PubMed ID: 16918403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation.
    Hamrang Z; Rattray NJ; Pluen A
    Trends Biotechnol; 2013 Aug; 31(8):448-58. PubMed ID: 23769716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharmaceutical nanoclusters: Towards the self-delivery of protein and peptide therapeutics.
    Danielsen M; Hempel C; Andresen TL; Urquhart AJ
    J Control Release; 2022 Jul; 347():282-307. PubMed ID: 35513210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopharmaceuticals from microorganisms: from production to purification.
    Jozala AF; Geraldes DC; Tundisi LL; Feitosa VA; Breyer CA; Cardoso SL; Mazzola PG; Oliveira-Nascimento L; Rangel-Yagui CO; Magalhães PO; Oliveira MA; Pessoa A
    Braz J Microbiol; 2016 Dec; 47 Suppl 1(Suppl 1):51-63. PubMed ID: 27838289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Green Therapeutic Biocapsules: Using Plant Cells to Orally Deliver Biopharmaceuticals.
    Rosales-Mendoza S; Nieto-Gómez R
    Trends Biotechnol; 2018 Oct; 36(10):1054-1067. PubMed ID: 29980327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals.
    Vass P; Démuth B; Hirsch E; Nagy B; Andersen SK; Vigh T; Verreck G; Csontos I; Nagy ZK; Marosi G
    J Control Release; 2019 Feb; 296():162-178. PubMed ID: 30677436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of lipidation in the development of advanced protein and peptide therapeutics.
    Menacho-Melgar R; Decker JS; Hennigan JN; Lynch MD
    J Control Release; 2019 Feb; 295():1-12. PubMed ID: 30579981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal models for evaluation of oral delivery of biopharmaceuticals.
    Harloff-Helleberg S; Nielsen LH; Nielsen HM
    J Control Release; 2017 Dec; 268():57-71. PubMed ID: 28935596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.
    Mandal A; Pal D; Agrahari V; Trinh HM; Joseph M; Mitra AK
    Adv Drug Deliv Rev; 2018 Feb; 126():67-95. PubMed ID: 29339145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diamonds in the rough: protein crystals from a formulation perspective.
    Jen A; Merkle HP
    Pharm Res; 2001 Nov; 18(11):1483-8. PubMed ID: 11758753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of carrier erythrocytes in delivery of biopharmaceuticals.
    Hamidi M; Zarrin A; Foroozesh M; Mohammadi-Samani S
    J Control Release; 2007 Apr; 118(2):145-60. PubMed ID: 17270305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
    Tibbitts J; Cavagnaro JA; Haller CA; Marafino B; Andrews PA; Sullivan JT
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):243-51. PubMed ID: 20558225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal delivery of biopharmaceuticals: dream or reality?
    Katikaneni S
    Ther Deliv; 2015; 6(9):1109-16. PubMed ID: 26419428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medipol: the guardian angel of biologics.
    Laue C; Ruppanner V
    Nanomedicine (Lond); 2006 Aug; 1(2):251-4. PubMed ID: 17716114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sub-visible particle quantitation in protein therapeutics.
    Cao S; Jiao N; Jiang Y; Mire-Sluis A; Narhi LO
    Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):73-9. PubMed ID: 20144454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.